心脏肌蛋白激活:对于静心性心力衰竭的潜在治疗方法
Fady I Malik1, James J Hartman, Kathleen A Elias
1Preclinical Research and Development, Cytokinetics, Inc., South San Francisco, CA 94080, USA. fmalik@cytokinetics.com
Science (New York, N.Y.)
|March 19, 2011
概括
一种新的心脏肌肉素激活剂Omecamtiv mecarbil通过增加喷射时间而不会改变收缩速度来增强心脏功能. 这种直接激活为静心性心力衰竭提供了一个有前途的治疗策略,绕过了传统的信号通路.
科学领域:
- 心脏病学 心脏病学
- 分子药理学分子药理学
- 生物化学 生物化学
背景情况:
- 静心性心力衰竭的特点是心脏收缩能力下降.
- 目前的治疗方法通过信号级联间接增强收缩性,导致与机制相关的不良影响.
- 奥梅卡姆提夫 (omecamtiv mecarbil) 被开发为一种小分子,直接激活心脏肌肉素,以克服这些局限性.
研究的目的:
- 为了阐明omecamtiv mecarbil的作用机制.
- 在动物模型中评估其对心脏功能的影响.
主要方法:
- 生物化学测试以确定结合部位和作用机制.
- 在体外研究中,研究了肌酸氨酸与动氨酸的相互作用.
- 在动物模型中对心脏功能进行体内评估.
主要成果:
- 欧美卡姆提夫麦卡尔比尔通过一种全osteric 机制与肌酸酶催化域结合.
- 它增加了肌肉素过渡到强烈结合乙烯酸的状态的速度.
- 该药物抑制了没有actin的ATP循环,表明了actin结合的肌构成的稳定.
- 在动物模型中,omecamtiv mecarbil通过延长喷射时间而改善心脏功能,而不会影响收缩率.
结论:
- 心脏肌蛋白激活代表了治疗心力衰竭的新疗法.
- 奥梅卡姆蒂夫麦卡尔比尔的直接激活机制避免了与间接信号通路相关的不良影响.
- 这种方法为心力衰竭提供了潜在的更安全,更有效的治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...